Lisa W. Chu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lisa W. Chu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Ann W. Hsing
Stanford Cancer Center, Stanford University, Palo Alto, CA, US
2 shared publications Kai Yu
National Cancer Institute, Rockville, MD, 2Cancer Prevention Institute of California, Fremont, CA
2 shared publications- Yu-Tang Gao
Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 201112, China
2 shared publications A P Chokkalingam
Department of Epidemiology, School of Public Health, University of California at Berkeley, Berkeley, CA, USA
1 shared publicationA W Hsing
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
1 shared publicationAnand P. Chokkalingam
Division of Epidemiology, School of Public Health, University of California at Berkeley, Berkeley, California
1 shared publication
Latest Publications
- 1 November 2012
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 21 (11_Supplem) , 32
Abstract 32: PER3 gene in association with plasma melatonin in Caucasian men.
Circadian rhythm disruption is classified as a possible human carcinogen, and has been associated with incidence, survival and prognosis of multiple cancers. Melatonin is the central circadian rhythm biomarker and identifying its genetic determinants will shed light on the mechanisms of the circadian rhythm-cancer relationship. We have conducted what we believe is the first genome wide association scan (GWAS) of morning circulating melatonin levels in humans. We used data from 1250 Caucasian men from the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). Serum used for melatonin measurements were prospectively collected and prediagnostic of cancer; all serum were collected in the morning (7:00-11:00 am). We evaluated ∼ 2.5 million single nucleotide polymorphisms (SNP), and gave priority to 1298 SNPs in 20 candidate genes related to melatonin and circadian rhythm (20 kb upstream-10 kb downstream). Single SNP analyses were performed using linear models for log transformed melatonin concentrations, coding SNPs additively, and adjusting for age (≤59, 60-64, 65-69, ≥70 years) time of blood draw (6-7, 8, 9, 10, 11 am), study center, prostate cancer status, and eigenvectors that captured population stratification. Gene based P-values (Pgene) were computed using the minP method and 10,000 permutations. For the most significant SNPs, we also performed sensitivity analyses by restricting the analysis to men who were not subsequently diagnosed with prostate cancer. We did not detect a signal at the genome-wide significance level (10-8). However, we observed that PER3, one of the 9 core circadian rhythm regulating genes, was significantly associated with serum melatonin after Bonferroni correction for the 20 a priori candidate genes (Pgene=9×10−4). The top SNP (SNP1-7763877 G>T) achieved significance after Bonferroni correction that takes into account the total number of SNPs (1298) in the 20 candidate genes selected (P=1.24×10−5). For this SNP, serum melatonin decreased by 28% (14.8-40%) per T allele. Our study suggests that PER3 gene polymorphisms might be associated with melatonin production, the velocity of diurnal decrease, or its diurnal pattern. This results warrant replication in independent samples, in females, and in urine for metabolites of melatonin. Citation Format: Fangyi Gu, Lisa W. Chu, Kai Yu, Zhaoming Wang, Stephen Chanock, Ann Hsing, Neil E. Caporaso. PER3 gene in association with plasma melatonin in Caucasian men. [abstract]. In: Proceedings of the AACR Special Conference on Post-GWAS Horizons in Molecular Epidemiology: Digging Deeper into the Environment; 2012 Nov 11-14; Hollywood, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(11 Suppl):Abstract nr 32.
- 1 November 2012
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 21 (11_Supplem) , 32
Abstract 32: PER3 gene in association with plasma melatonin in Caucasian men.
Circadian rhythm disruption is classified as a possible human carcinogen, and has been associated with incidence, survival and prognosis of multiple cancers. Melatonin is the central circadian rhythm biomarker and identifying its genetic determinants will shed light on the mechanisms of the circadian rhythm-cancer relationship. We have conducted what we believe is the first genome wide association scan (GWAS) of morning circulating melatonin levels in humans. We used data from 1250 Caucasian men from the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). Serum used for melatonin measurements were prospectively collected and prediagnostic of cancer; all serum were collected in the morning (7:00-11:00 am). We evaluated ∼ 2.5 million single nucleotide polymorphisms (SNP), and gave priority to 1298 SNPs in 20 candidate genes related to melatonin and circadian rhythm (20 kb upstream-10 kb downstream). Single SNP analyses were performed using linear models for log transformed melatonin concentrations, coding SNPs additively, and adjusting for age (≤59, 60-64, 65-69, ≥70 years) time of blood draw (6-7, 8, 9, 10, 11 am), study center, prostate cancer status, and eigenvectors that captured population stratification. Gene based P-values (Pgene) were computed using the minP method and 10,000 permutations. For the most significant SNPs, we also performed sensitivity analyses by restricting the analysis to men who were not subsequently diagnosed with prostate cancer. We did not detect a signal at the genome-wide significance level (10-8). However, we observed that PER3, one of the 9 core circadian rhythm regulating genes, was significantly associated with serum melatonin after Bonferroni correction for the 20 a priori candidate genes (Pgene=9×10−4). The top SNP (SNP1-7763877 G>T) achieved significance after Bonferroni correction that takes into account the total number of SNPs (1298) in the 20 candidate genes selected (P=1.24×10−5). For this SNP, serum melatonin decreased by 28% (14.8-40%) per T allele. Our study suggests that PER3 gene polymorphisms might be associated with melatonin production, the velocity of diurnal decrease, or its diurnal pattern. This results warrant replication in independent samples, in females, and in urine for metabolites of melatonin. Citation Format: Fangyi Gu, Lisa W. Chu, Kai Yu, Zhaoming Wang, Stephen Chanock, Ann Hsing, Neil E. Caporaso. PER3 gene in association with plasma melatonin in Caucasian men. [abstract]. In: Proceedings of the AACR Special Conference on Post-GWAS Horizons in Molecular Epidemiology: Digging Deeper into the Environment; 2012 Nov 11-14; Hollywood, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(11 Suppl):Abstract nr 32.
- Open Access
Identification of Serum Biomarkers for Biliary Tract Cancers by a Proteomic Approach Based on Time-of-Flight Mass Spectrometry
Biliary tract cancers (BTCs) are lethal malignancies currently lacking satisfactory methods for early detection and accurate diagnosis. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) is a promising diagnostic tool for this disease. In this pilot study, sera samples from 50 BTCs and 30 cholelithiasis patients as well as 30 healthy subjects from a population-based case-control study were randomly grouped into training set (30 BTCs, 20 cholelithiasis and 20 controls), duplicate of training set, and blind set (20 BTCs, 10 cholelithiasis and 10 controls); all sets were analyzed on Immobilized Metal Affinity Capture ProteinChips via SELDI-TOF-MS. A decision tree classifier was built using the training set and applied to all test sets. The classification tree constructed with the 3,400, 4,502, 5,680, 7,598, and 11,242 mass-to-charge ratio (m/z) protein peaks had a sensitivity of 96.7% and a specificity of 85.0% when comparing BTCs with non-cancers. When applied to the duplicate set, sensitivity was 66.7% and specificity was 70.0%, while in the blind set, sensitivity was 95.0% and specificity was 75.0%. Positive predictive values of the training, duplicate, and blind sets were 82.9%, 62.5% and 79.2%, respectively. The agreement of the training and duplicate sets was 71.4% (Kappa = 0.43, u = 3.98, P < 0.01). The coefficient of variations based on 10 replicates of one sample for the five differential peaks were 15.8–68.8% for intensity and 0–0.05% for m/z. These pilot results suggest that serum protein profiling by SELDI-TOF-MS may be a promising approach for identifying BTCs but low assay reproducibility may limit its application in clinical practice.
Open AccessIdentification of Serum Biomarkers for Biliary Tract Cancers by a Proteomic Approach Based on Time-of-Flight Mass Spectrometry
Biliary tract cancers (BTCs) are lethal malignancies currently lacking satisfactory methods for early detection and accurate diagnosis. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) is a promising diagnostic tool for this disease. In this pilot study, sera samples from 50 BTCs and 30 cholelithiasis patients as well as 30 healthy subjects from a population-based case-control study were randomly grouped into training set (30 BTCs, 20 cholelithiasis and 20 controls), duplicate of training set, and blind set (20 BTCs, 10 cholelithiasis and 10 controls); all sets were analyzed on Immobilized Metal Affinity Capture ProteinChips via SELDI-TOF-MS. A decision tree classifier was built using the training set and applied to all test sets. The classification tree constructed with the 3,400, 4,502, 5,680, 7,598, and 11,242 mass-to-charge ratio (m/z) protein peaks had a sensitivity of 96.7% and a specificity of 85.0% when comparing BTCs with non-cancers. When applied to the duplicate set, sensitivity was 66.7% and specificity was 70.0%, while in the blind set, sensitivity was 95.0% and specificity was 75.0%. Positive predictive values of the training, duplicate, and blind sets were 82.9%, 62.5% and 79.2%, respectively. The agreement of the training and duplicate sets was 71.4% (Kappa = 0.43, u = 3.98, P < 0.01). The coefficient of variations based on 10 replicates of one sample for the five differential peaks were 15.8–68.8% for intensity and 0–0.05% for m/z. These pilot results suggest that serum protein profiling by SELDI-TOF-MS may be a promising approach for identifying BTCs but low assay reproducibility may limit its application in clinical practice.
- Open Access
- 1 November 2008
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 17 (11) , 3268-3273
Correlation between Circadian Gene Variants and Serum Levels of Sex Steroids and Insulin-like Growth Factor-I
A variety of biological processes, including steroid hormone secretion, have circadian rhythms, which are influenced by nine known circadian genes. Previously, we reported that certain variants in circadian genes were associated with risk for prostate cancer. To provide some biological insight into these findings, we examined the relationship of five variants of circadian genes, including NPAS2 (rs2305160:G>A), PER1 (rs2585405:G>C), CSNK1E (rs1005473:A>C), PER3 (54-bp repeat length variant), and CRY2 (rs1401417:G>C), with serum levels of sex steroids and insulin-like growth factor (IGF)-I and IGF-binding protein 3 (IGFBP3) in 241 healthy elderly Chinese men (mean age of 71.5). Age-adjusted and waist-to-hip ratio–adjusted ANOVA followed by likelihood ratio tests (LRT) showed that the NPAS2 variant A allele was associated with lower free and bioavailable testosterone (PLRT = 0.02 and 0.01, respectively) compared with the GG genotype. In addition, the PER1 variant was associated with higher serum levels of sex hormone-binding globulin levels (Ptrend = 0.03), decreasing 5α-androstane-3α, 17β-diol glucuronide levels (Ptrend = 0.02), and decreasing IGFBP3 levels (Ptrend = 0.05). Furthermore, the CSNK1E variant C allele was associated with higher testosterone to dihydrotestosterone ratios (PLRT = 0.01) compared with the AA genotype, whereas the longer PER3 repeat was associated with higher serum levels of IGF-I (PLRT = 0.03) and IGF-I to IGFBP3 ratios (PLRT = 0.04). The CRY2 polymorphism was not associated with any biomarkers analyzed. Our findings, although in need of confirmation, suggest that variations in circadian genes are associated with serum hormone levels, providing biological support for the role of circadian genes in hormone-related cancers. (Cancer Epidemiol Biomarkers Prev 2008;17(11):3268–73)
- 1 November 2008
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 17 (11) , 3268-3273
Open AccessCorrelation between Circadian Gene Variants and Serum Levels of Sex Steroids and Insulin-like Growth Factor-I
A variety of biological processes, including steroid hormone secretion, have circadian rhythms, which are influenced by nine known circadian genes. Previously, we reported that certain variants in circadian genes were associated with risk for prostate cancer. To provide some biological insight into these findings, we examined the relationship of five variants of circadian genes, including NPAS2 (rs2305160:G>A), PER1 (rs2585405:G>C), CSNK1E (rs1005473:A>C), PER3 (54-bp repeat length variant), and CRY2 (rs1401417:G>C), with serum levels of sex steroids and insulin-like growth factor (IGF)-I and IGF-binding protein 3 (IGFBP3) in 241 healthy elderly Chinese men (mean age of 71.5). Age-adjusted and waist-to-hip ratio–adjusted ANOVA followed by likelihood ratio tests (LRT) showed that the NPAS2 variant A allele was associated with lower free and bioavailable testosterone (PLRT = 0.02 and 0.01, respectively) compared with the GG genotype. In addition, the PER1 variant was associated with higher serum levels of sex hormone-binding globulin levels (Ptrend = 0.03), decreasing 5α-androstane-3α, 17β-diol glucuronide levels (Ptrend = 0.02), and decreasing IGFBP3 levels (Ptrend = 0.05). Furthermore, the CSNK1E variant C allele was associated with higher testosterone to dihydrotestosterone ratios (PLRT = 0.01) compared with the AA genotype, whereas the longer PER3 repeat was associated with higher serum levels of IGF-I (PLRT = 0.03) and IGF-I to IGFBP3 ratios (PLRT = 0.04). The CRY2 polymorphism was not associated with any biomarkers analyzed. Our findings, although in need of confirmation, suggest that variations in circadian genes are associated with serum hormone levels, providing biological support for the role of circadian genes in hormone-related cancers. (Cancer Epidemiol Biomarkers Prev 2008;17(11):3268–73)
- Open Access
- 6 November 2007
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 11 (4) , 342-348
Variants in circadian genes and prostate cancer risk: a population-based study in China
Circadian genes influence a variety of biological processes that are important in prostate tumorigenesis including metabolism. To determine if variants in circadian genes alter prostate cancer risk, we genotyped five variants in five circadian genes in a population-based case–control study conducted in China (187 cases and 242 controls). These variants included CRY2 rs1401417:G>C, CSNK1E rs1005473:A>C, NPAS2 rs2305160:G>A, PER1 rs2585405:G>C and PER3 54-bp repeat length variant. Men with the cryptochrome 2 (CRY2)-variant C allele had a significant 1.7-fold increased prostate cancer risk (95% confidence interval (CI), 1.1–2.7) relative to those with the GG genotype. This risk increased to 4.1-fold (95% CI, 2.2–8.0) in men who also had greater insulin resistance (IR) as compared to men with the GG genotype and less IR. In contrast, among men with less IR, the NPAS2-variant A allele was associated with decreased prostate cancer risk (odds ratio=0.5, 95% CI, 0.3–1.0) as compared to the GG genotype. Our findings, although in need of confirmation, suggest that variations in circadian genes may alter prostate cancer risk and some biological processes may modify this effect.
- 6 November 2007
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 11 (4) , 342-348
Open AccessVariants in circadian genes and prostate cancer risk: a population-based study in China
Circadian genes influence a variety of biological processes that are important in prostate tumorigenesis including metabolism. To determine if variants in circadian genes alter prostate cancer risk, we genotyped five variants in five circadian genes in a population-based case–control study conducted in China (187 cases and 242 controls). These variants included CRY2 rs1401417:G>C, CSNK1E rs1005473:A>C, NPAS2 rs2305160:G>A, PER1 rs2585405:G>C and PER3 54-bp repeat length variant. Men with the cryptochrome 2 (CRY2)-variant C allele had a significant 1.7-fold increased prostate cancer risk (95% confidence interval (CI), 1.1–2.7) relative to those with the GG genotype. This risk increased to 4.1-fold (95% CI, 2.2–8.0) in men who also had greater insulin resistance (IR) as compared to men with the GG genotype and less IR. In contrast, among men with less IR, the NPAS2-variant A allele was associated with decreased prostate cancer risk (odds ratio=0.5, 95% CI, 0.3–1.0) as compared to the GG genotype. Our findings, although in need of confirmation, suggest that variations in circadian genes may alter prostate cancer risk and some biological processes may modify this effect.